

## Author index to Volume 39, 2002

(C) = Comment: (PV) = Personal View: (RA) = Review Article: (ER) = Evidence-based Review:  
(OA) = Original Article: (SR) = Short Report: (CR) = Case Report: (L) = Letter.

- Abdella N. *see* Mojiminiyi OA  
 Abdul-Razzak R. *see* Mojiminiyi OA  
 Aitken DA. *see* Spencer K  
 Akçay F, Aksoy H, Memişoğlu R: Effect of breast-feeding on concentration of nitric oxide in breast milk, 68 (SR)  
 Akita H, Matsubara M, Shibuya H, Fuda H, Chiba H: Effect of ageing on plasma lipoprotein(a) levels, 237 (OA)  
 Aksoy H. *see* Akçay F  
 Alaghband-Zadeh J. *see* le Roux CW  
 Alberti KGMM. *see* Emberson JR  
 Albright SV, McCart JA, Libutti SK, Bartlett DL, Alexander HR, Sampson ML, Ruddel ME, Remaley AT: Rapid measurement of insulin using the Abbot IMx: application to the management of insulinoma, 513 (SR)  
 Alexander HR. *see* Albright SV  
 Allen KR. *see* Carling RS  
 Ameerally P. *see* Crook MA  
 Anderson NR. *see* Elfatih A; Gama R  
 Andrew CE. *see* Vivekanandan S  
 Andrews DJ, Cramb R: Cyclosporin: revisions in monitoring guidelines and review of current analytical methods, 424 (PV)  
 Arasradnam MP, Morgan L, Wright J, Gama R: Diurnal variation in lipoprotein lipase activity, 136 (OA)  
 Armston A, Bulusu S: Audit of investigation of subclinical hypothyroidism in Scottish laboratories, 535 (L)  
 Armston A, Wood P: Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis?, 184 (PV)  
 Aujuard Y. *see* Guibourdenche J  
 Badrick T. *see* Campbell B  
 Badrick T, Hickman PE: Reporting of creatinine concentration, 162 (L)  
 Bakkouch K. *see* Lefèvre G  
 Balazs NDH. *see* Newman JD  
 Bandín J. *see* Camacho T  
 Barclay ML. *see* Owen MC  
 Barfield CP. *see* Newman JD  
 Barron JL. *see* Chandra R  
 Barth JH. *see* Carling RS; Ismail AAA; Marshall SM; Thomson JDR  
 Bartlett DL. *see* Albright SV  
 Bax NDS. *see* Carling RS  
 Baxter GJ, Lawrence JR, Graham AB, Wiles D, Paterson JR: Identification and determination of salicylic acid and salicyluric acid in urine of people not taking salicylate drugs, 50 (OA)  
 Bayly G: HDL-cholesterol and cardiac disease: which table to use?, 12 (RA)  
 Becker P. *see* van der Merwe D  
 Beckett G. *see* Clark PM  
 Bedu A. *see* Guibourdenche J  
 Beilby JP. *see* Ching SYL  
 Berry P: Audit of investigation of subclinical hypothyroidism in Scottish laboratories, 26 (OA); Audit of investigation of subclinical hypothyroidism in Scottish laboratories - author's reply, 536 (L)  
 Blennerhassett J. *see* Sheehan P  
 Blumsohn A, Hadari A Al: Parathyroid hormone: what are we measuring and does it matter?, 169 (C)  
 Boeck AT, Fry DL, Sastre A, Lockridge O: Naturally occurring mutation, Asp70His, in human butyrylcholinesterase, 154 (SR)  
 Bonetti G. *see* Pagani F  
 Bonora R. *see* Pagani F  
 Bossuyt X, Sneyers L, Mariën G, Vranken G: Novel nephelometric assay for measurement of complement 3d, 34 (OA)  
 Brandslund I. *see* Petersen PH  
 Broughton A. *see* Lang T; Lawson N  
 Buckley KA, Fraser WD: Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses, and potential therapeutic agents and biochemical markers, 551 (RA)  
 Bulusu S. *see* Armston A  
 Burnett JR. *see* Burnett L  
 Burnett JR, Vasikaran SD: Cardiovascular disease and osteoporosis: is there a link between lipids and bone?, 203 (RA)  
 Burnett L, Chesher D, Burnett JR: Optimizing the availability of 'stat' laboratory tests using Shewhart 'c' control charts, 140 (OA)

- Cabrera-Abreu JC, Green A:** g-Glutamyltransferase: value of its measurement in paediatrics, 22 (RA)
- Camacho T, Mora J, Segura A, Guitián J, Lema F, Bandin J, Rodríguez-Espinosa J:** Falsely increased prostate-specific antigen concentration attributed to heterophilic antibodies, 160 (CR)
- Campbell B, Badrick T, Flatman R, Kanowski D:** Limited clinical utility of high-sensitivity plasma C-reactive protein assays, 85 (C)
- Capeau J.** *see* Lefèvre G
- Carling RS, Degg TJ, Allen KR, Bax NDS, Barth JH:** Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease, 577 (OA)
- Carling RS, Hextall R, DeSilva PA, Barth JH:** Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy, 409 (CR)
- Cassidy MJD.** *see* Godber IM
- Cawood ML.** *see* Ismail AAA
- Chandra R, Barron JL:** Anaphylactic reaction to intravenous sinistrin (Inutest), 76 (CR)
- Chattha K.** *see* Elfatih A
- Chesher D.** *see* Burnett L
- Chiba H.** *see* Akita H
- Chin D.** *see* Nageh T
- Ching SYL, Prins AW, Beilby JP:** Stability of ascorbic acid in serum and plasma prior to analysis, 518 (SR)
- Chun S II.** *see* Hong SH
- Clark PM, Beckett G:** Can we measure serum thyroglobulin?, 196 (PV)
- Coakley JC.** *see* Williams AJ
- Coleman MM.** *see* Hogg JE
- Cooke JC.** *see* Nageh T
- Cooper DP.** *see* Keevil BG
- Cooper RG.** *see* Gray TA
- Cramb R.** *see* Andrews DJ
- Crook MA, Goldsmith L, Ameerally P, Lumb P, Singh N, Miell J, Russell-Jones D:** Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose, 606 (SR)
- Crossley JA.** *see* Spencer K
- Davidson, DF:** Pheochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines, 557 (OA)
- Davidson DF:** Effects of contamination of blood specimens with liquid potassium-EDTA anticoagulant, 273 (OA)
- de Vries JCM.** *see* Groothuis S
- Degg TJ.** *see* Carling RS
- Delport R.** *see* van der Merwe D
- DeSilva PA.** *see* Carling RS
- Devgun MS.** *see* Ross CM
- Dhatt GS.** *see* van der Merwe D
- Dhawan IK.** *see* Thakur V
- Dhillon W.** *see* le Roux CW
- Drupsteen EJ.** *see* Groothuis S
- Dunstan FDJ.** *see* Spencer K
- Egner W.** *see* Patel D
- Elfatih A, Chattha K, Anderson NR, Gama R:** Limited clinical utility of high-sensitivity plasma C-reactive protein assays, 536 (L)
- Elfatih AB.** *see* Gama R
- Emberson JR, Whincup PH, Walker M, Thomas M, Alberti KGMM:** Biochemical measures in a population-based study: effect of fasting duration and time of day, 493 (OA)
- Ewer AK.** *see* Peet AC
- Faye, S:** Immulite 2000 LH assay: manufacturer's reply, 417 (L)
- Ferns GA.** *see* Saadeddin SM
- Fielding AM, Powell A:** Using Medline to achieve an evidence-based approach to diagnostic clinical biochemistry, 345 (PV)
- Flatman R.** *see* Campbell B
- Florkowski CM.** *see* Owen MC
- Fraser CG.** *see* Petersen PH
- Fraser WD.** *see* Buckley KA
- Freedman DB:** Clinical governance: implications for point-of-care testing, 421 (C)
- Fry DL.** *see* Boeck AT
- Fucharoen G.** *see* Fucharoen S
- Fucharoen S, Fucharoen G, Sanchaisuriya K, Pengiam Y:** Molecular analysis of a Thai  $\beta$ -thalassaemia heterozygote with normal haemoglobin A<sub>2</sub> level: implication for population screening, 44 (OA)
- Fuda H.** *see* Akita H
- Fukui A.** *see* Takatani T
- Gaffney D.** *see* Hogg JE
- Galloway J.** *see* Gray TA
- Gama R.** *see* Arasaradnam MP; Elfatih A
- Gama R, Elfatih AB, Anderson NR:** Ethnic differences in total and HDL cholesterol concentrations: Caucasians compared with predominately Punjabi Sikh Indo-Asians, 609 (SR)
- Garbarz E.** *see* Lefèvre G
- George PM.** *see* Owen MC
- Gill J.** *see* Vasikaran SD
- Gleeson D.** *see* Patel D
- Godber IM, Parker CR, Lawson N, Hitch T, Porter CJ, Roe SD, Cassidy MJD, Hosking DJ:** Comparison of intact and 'whole molecule' parathyroid hormone

- assays in patients with histologically confirmed post-renal transplant osteodystrophy, 314 (SR)
- Goldschmidt HMJ.** *see* Groothuis S
- Goldsmith L.** *see* Crook MA
- Gowans EMS.** *see* Petersen PH
- Graham AB.** *see* Baxter GJ
- Graïne H.** *see* Lefèvre G
- Gray TA, Cooper RG, Galloway J, Marples J:** Quarts out of pint pots – expanding the pint. Clinical budgeting in practice, 340 (PV)
- Green A.** *see* Cabrera-Abreu JC; Hardy DT; Preece MA: Biochemical investigations in patients with dementia, 211 (RA)
- Griffiths K.** *see* Pumford SLA
- Groothuis S, Goldschmidt HMJ, Drupsteen EJ, de Vries JCM, Hasman A, van Merode GG:** Application of computer simulation analysis to assess the effects of relocating a hospital phlebotomy department, 261 (OA)
- Guibourdenche J, Bedu A, Petzold L, Marchand M, Mariani-Kurdjian P, Hurtaud-Roux M-F, Aujard Y, Porquet D:** Biochemical markers of neonatal sepsis: value of procalcitonin in the emergency setting, 130 (OA)
- Guitián J.** *see* Camacho T
- Gunn IR.** *see* Ross CM: Troponin for acute coronary syndromes, 621 (L)
- Habbab MA.** *see* Saadeddin SM
- Hadari A Al.** *see* Blumsohn A
- Hall SK.** *see* Hardy DT
- Hancock MR:** Mitochondrial dysfunction and the role of the non-specialist laboratory, 456 (RA)
- Hanning I, Mires GJ:** Triploid pregnancy detected incidentally by Down's syndrome screening, 157 (CR)
- Hanyu O.** *see* Miida T
- Hardy DT, Hall SK, Preece MA, Green A:** Quantitative determination of plasma phenylalanine and tyrosine by electrospray ionization tandem mass spectrometry, 73 (SR)
- Harris T.** *see* Huo ZM
- Hashida S.** *see* Hirota K
- Hasman A.** *see* Groothuis S
- Hata Y.** *see* Hirota R
- Hawkins R:** Discrepancy between visual and spectrophotometric assessment of sample haemolysis, 521 (SR)
- Hayward Vermaak WJ.** *see* van der Merwe D
- Hector RD.** *see* Hogg JE
- Hextall R.** *see* Carling RS
- Hickman PE.** *see* Badrick T
- Hikiji K.** *see* Hirota R
- Hirota K, Kamashima T, Hashida S, Totani M:** Immune complex transfer enzyme immunoassay for anti-ovalbumin IgA in serum, 482 (OA)
- Hirota R, Kubo N, Hikiji K, Nakajima K, Hata Y, Sakurabayashi I:** Japanese familial hypercholesterolaemia with a 327insC mutation in the LDL receptor gene, 526 (CS)
- Hitch T.** *see* Godber IM
- Hocking MD.** *see* Peet AC
- Hogg JE, Gaffney D, Hector RD, Coleman MM, Wallace AM:** Application of polymerase chain reaction with oligoligation assay to determine genotype in individuals presenting with congenital adrenal hyperplasia, 293 (OA)
- Hokari S.** *see* Kawai S
- Holding S:** Current state of screening for Down's syndrome, 1 (RA)
- Holt DW:** Monitoring mycophenolic acid, 173 (PV)
- Home PD.** *see* Marshall SM
- Hong SH, Kim Y-R, Yoon YM, Min WK, Chun S II, Kim JQ:** Association between *HaeIII* polymorphism of scavenger receptor class B type I gene and plasma HDL-cholesterol concentration, 478 (OA)
- Horikawa Y.** *see* Miida T
- Hosking DJ.** *see* Godber IM
- Huo ZM, Miles J, Riches PG, Harris T:** Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay, 398 (OA)
- Hurtaud-Roux M-F.** *see* Guibourdenche J
- Imai K.** *see* Masuda M
- Imai T.** *see* Itoh S
- Ismail AAA, Walker PL, Cawood ML, Barth JH:** Interference in immunoassay is an underestimated problem, 366 (PV)
- Isobe K.** *see* Itoh S
- Itoh S, Kawada K, Kusaka T, Yasuda S, Okada H, Imai T, Isobe K:** Influence of glucuronosyl bilirubin and (EZ)-cyclobilirubin on determination of serum unbound bilirubin by UB-analyser, 583 (OA)
- Izawa S.** *see* Miida T
- John G.** *see* Marshall SM
- John WG.** *see* Marshall SM
- Jørgensen L.** *see* Petersen PH
- Joyce HJ.** *see* Maguire GA
- Kamashima T.** *see* Hirota K
- Kanowski D.** *see* Campbell B
- Kawada K.** *see* Itoh S
- Kawai K.** *see* Kawai S
- Kawai S, Nakajima T, Hokari S, Komoda T, Kawai K:** Apolipoprotein A-I concentration in tears in diabetic retinopathy, 56 (OA)
- Keevil BG, McCann SJ, Cooper DP, Morris MR:** Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry, 487 (OA)

- Kennedy DM. *see* Peet AC  
 Kim JQ. *see* Hong SH  
 Kim Y-R. *see* Hong SH  
 Kokuba Y. *see* Sasamura T  
 Komoda T. *see* Kawai S  
 Kong WM. *see* le Roux CW  
 Kortom M. *see* Mojiminiyi OA  
 Kricka LJ: Stains, labels and detection strategies for nucleic acids assays, 114 (RA)  
 Kubo N. *see* Hirota R  
 Kumar R. *see* Thakur V  
 Kumararatne DS. *see* Maguire GA  
 Kusaka T. *see* Itoh S
- Lamb EJ. *see* Payn MM  
 Lang T. *see* Lawson N  
 Lang T, Prinsloo P, Broughton A, Lawson N, Marenah CB: Effect of low protein concentration on serum sodium measurement: pseudohyponatraemia and pseudonormonatraemia!, 66 (SR)  
 Lawrence D. *see* Payn MM  
 Lawrence JR. *see* Baxter GJ  
 Lawson N. *see* Godber IM; Lang T  
 Lawson N, Lang T, Broughton A, Prinsloo P, Turner C, Marenah C: Creatinine assays: time for action?, 599 (SR)  
 le Roux CW, Meeran K, Alagband-Zadeh J: Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?, 148 (SR)  
 le Roux CW, Sivakumaran S, Alagband-Zadeh J, Dhillon W, Kong WM, Wheeler MJ: Free cortisol index as a surrogate marker for serum free cortisol, 406 (SR)  
 Lefèvre G, Graëne H, Bakkouch K, Garbarz E, Marlin G, Michel PL, Capeau J: Evaluation of Kryptor cardiac troponin I immunoassay, 145 (SR)  
 Lema F. *see* Camacho T  
 Libeer J-C. *see* Petersen PH  
 Libutti SK. *see* Albright SV  
 Lockridge O. *see* Boeck AT  
 Losty H: Faecal fat: time to give it up, 77 (L)  
 Lumb P. *see* Crook MA
- Mackintosh AF. *see* Thomson JDR  
 Maguire GA, Kumararatne DS, Joyce HJ: Are there any clinical indications for measuring IgG subclasses?, 374 (RA)  
 Manley SE. *see* Marshall SM  
 Marchand M. *see* Guibourdenche J  
 Marenah C. *see* Lawson N  
 Marenah CB. *see* Lang T  
 Mariani-Kurdjian P. *see* Guibourdenche J  
 Mariën G. *see* Bossuyt X  
 Marlin G. *see* Lefèvre G  
 Marouf R. *see* Mojiminiyi OA  
 Marples J. *see* Gray TA  
 Marshall SM, Home PD, John G, Manley SE: Standardization of glycated haemoglobin - authors' reply, 534 (L)  
 Marshall SM, Home PD, Manley SE, Barth JH, John WG: Standardization of glycated haemoglobin, 78 (L)  
 Maruyama S. *see* Miida T  
 Masuda M, Tsunoda M, Yusa Y, Yamada S, Imai K: Assay of catechol-O-methyltransferase activity in human erythrocytes using norepinephrine as a natural substrate, 589 (OA)  
 Masutani T. *see* Takatani T  
 Matsubara M. *see* Akita H  
 Matsuda A. *see* Sasamura T  
 Matsui H. *see* Miida T  
 McCann SJ. *see* Keevil BG  
 McCart JA. *see* Albright SV  
 McConnell W, Vasikaran SD: Spot urine analysis: acidification does not increase calcium recovery, 64 (SR)  
 Meehan N. *see* Nageh T  
 Meeran K. *see* le Roux CW  
 Memişoğlu R. *see* Akçay F  
 Mezaki T. *see* Miida T  
 Michel PL. *see* Lefèvre G  
 Middle J: Standardization of glycated haemoglobin, 534 (L)  
 Miell J. *see* Crook MA  
 Miida T, Nakamura Y, Mezaki T, Hanyu O, Maruyama S, Horikawa Y, Izawa S, Yamada Y, Matsui H, Okada M: LDL-cholesterol and HDL-cholesterol concentrations decrease during the day, 241 (OA)  
 Miles J. *see* Huo ZM  
 Mills GA. *see* Walker V  
 Min WK. *see* Hong SH  
 Mires GJ. *see* Hanning I  
 Miwa I, Suzuki S: An improved quantitative assay of glycogen in erythrocytes, 612 (SR)  
 Mojiminiyi OA, Marouf R, Abdella N, Kortom M, Abdul-Razzak R: Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders, 308 (SR)  
 Monaghan MJ. *see* Nageh T  
 Mora J. *see* Camacho T  
 Morgan L. *see* Arasaradnam MP  
 Morita K. *see* Takatani T  
 Morris MR. *see* Keevil BG  
 Morton MM. *see* Pumford SL  
 Muller BR: Analysis of serum angiotensin-converting enzyme, 436 (PV)  
 Murakawa K. *see* Takatani T
- Nageh T, Chin D, Cooke JC, Meehan N, Monaghan MJ, Sherwood RA: Interpretation of plasma brain

- natriuretic peptide concentrations may require adjustment for patient's age, 151 (SR)
- Nakajima K.** *see* Hirota R
- Nakajima T.** *see* Kawai S
- Nakamura Y.** *see* Miida T
- National Poisons Information Service and Association of Clinical Biochemists:** Laboratory analyses for poisoned patients: joint position paper, 328 (G)
- Nelson-Piercy C.** *see* Walker IAL
- Newman DJ:** Cystatin C, 89 (PV)
- Newman JD, Pecache NS, Barfield CP, Balazs NDH:** Point-of-care testing of blood glucose in the neonatal unit using the AVL Omni 9 analyser, 509 (OA)
- Nishimura M.** *see* Ohta M
- Nix ABJ.** *see* Spencer K
- Norris L.** *see* Williams AJ
- Ohta K.** *see* Ohta M
- Ohta M, Ohta K, Nishimura M, Saida T:** Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, 603 (SR)
- Okada H.** *see* Itoh S
- Okada M.** *see* Miida T
- Okamoto Y.** *see* Takatani T
- Okuno Y.** *see* Takatani T
- Owen MC, Pike LS, George PM, Barclay ML, Florkowski CM:** Macro-alkaline phosphatase due to IgG  $\kappa$  complex: demonstration with polyethylene glycol precipitation and immunofixation, 523 (CR)
- Pagani F, Bonora R, Bonetti G, Panteghini M:** Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein, 404 (SR)
- Panteghini M.** *see* Pagani F
- Parker CR.** *see* Godber IM
- Patel D, Egner W, Gleeson D, Wild G, Ward A:** Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay is potentially less specific than by immunofluorescence, 304 (OA)
- Paterson JR.** *see* Baxter GJ
- Payn MM, Lawrence D, Willis R, Lamb EJ:** Sample matrix is critical in the evaluation of a dry-slide bromocresol green method for human albumin, 311 (SR)
- Peake MJ, White GH:** Arterial blood gas analysis: selecting the clinically appropriate option for calculating base excess, 614 (CR)
- Pecache NS.** *see* Newman JD
- Peet AC, Kennedy DM, Hocking MD, Ewer AK:** Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit, 502 (OA)
- Penberthy L.** *see* Vasikaran SD
- Pengiam Y.** *see* Fucharoen S
- Petersen PH, Fraser CG, Jørgensen L, Brandslund I, Stahl M, Gowans EMS, Libeer J-C, Ricós C:** Combination of analytical quality specifications based on biological within- and between-subject variation, 543 (PV)
- Petzold L.** *see* Guibourdenche J
- Pike LS.** *see* Owen MC
- Piscator, 83, 167, 325, 420, 542, 627**
- Porquet D.** *see* Guibourdenche J
- Porter CJ.** *see* Godber IM
- Powell A.** *see* Fielding AM
- Preece MA.** *see* Hardy DT
- Preece MA, Green A:** Pregnancy and inherited metabolic disorders: maternal and fetal complications, 444 (RA)
- Prins AW.** *see* Ching SYL
- Prinsloo P.** *see* Lang T; Lawson N
- Pumford SL, Morton MM, Turkes A, Griffiths K:** Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry, 281 (OA)
- Rainbow S.** *see* Sharp P
- Remaley AT.** *see* Albright SV
- Riches PG.** *see* Huo ZM
- Ricós C.** *see* Petersen PH
- Rodríguez-Espinosa J.** *see* Camacho T
- Roe SD.** *see* Godber IM
- Ross CM, Devgun MS, Gunn IR:** Hyperamylasaemia and multiple myeloma, 616 (CR)
- Ruddel ME.** *see* Albright SV
- Russell-Jones D.** *see* Crook MA
- Saadeddin SM, Habbab MA, Sobki SH, Ferns GA:** Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome, 392 (OA)
- Saida T.** *see* Ohta M
- Sakurabayashi I.** *see* Hirota R
- Sampson ML.** *see* Albright SV
- Sanchaisuriya K.** *see* Fucharoen S
- Sasamura T, Matsuda A, Kokuba Y:** Determination of D-amino acid oxidase activity in tumour cells, 595 (OA)
- Sastre A.** *see* Boeck AT
- Scott S.** *see* Vasikaran SD
- Segura A.** *see* Camacho T
- Sharp P, Rainbow S:** Continuous glucose monitoring and haemoglobin A<sub>1c</sub>, 516 (SR)
- Sharpe P:** Survival after very high blood alcohol concentrations, author's reply, 416 (L)



- Sheehan P, Blennerhassett J, Vasikaran SD:** Decision limit for troponin I and assay performance, 231 (OA)
- Sherwood RA.** *see* Nageh T
- Shibuya H.** *see* Akita H
- Sikaris KA.** *see* Vasikaran SD
- Singh N.** *see* Crook MA
- Sivakumaran S.** *see* le Roux CW
- Sneyers L.** *see* Bossuyt X
- Sobki SH.** *see* Saadeddin SM
- Spencer K, Crossley JA, Aitken DA, Nix ABJ, Dunstan FDJ, Williams K:** Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy, 567 (OA)
- Stahl M.** *see* Petersen PH
- Starkey BJ:** Screening for colorectal cancer, 351 (PV)
- Suzuki S.** *see* Miwa I
- Takaoka N.** *see* Takatani T
- Takatani T, Morita K, Takaoka N, Tatsumi M, Okuno Y, Masutani T, Murakawa K, Fukui A, Tsukaguchi N, Okamoto Y:**  $\gamma$  Heavy chain disease screening showing a discrepancy between electrophoretic and nephelometric determinations of serum  $\gamma$  globulin concentration, 531 (CR)
- Tatsumi M.** *see* Takatani T
- Thakur V, Kumar R, Dhawan IK:** Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients, 70 (SR)
- Thomas M.** *see* Emberson JR
- Thomas SHL, Watson ID:** Laboratory analyses for poisoned patients, 327 (C)
- Thomson JDR, Mackintosh AF, Barth JH:** Troponin for acute coronary syndromes: has NICE got it right?, 194 (PV)
- Totani M.** *see* Hirota K
- Tsukaguchi N.** *see* Takatani T
- Tsunoda M.** *see* Masuda M
- Turkes A.** *see* Pumford SL
- Turner C.** *see* Lawson N
- Ubbink JB.** *see* van der Merwe D
- van der Merwe D, Ubbink JB, Delport R, Becker P, Dhath GS, Hayward Vermaak WJ:** Biological variation in sweat sodium chloride conductivity, 39 (OA)
- van Heyningen C, Watson ID:** Survival after very high blood alcohol concentrations, 416 (L)
- van Merode GG.** *see* Groothuis S
- Vasikaran SD.** *see* Burnett JR; McConnell W; Sheehan P
- Vasikaran SD, Penberthy L, Gill J, Scott S, Sikaris KA:** Review of a pilot quality-assessment program for interpretative comments, 250 (OA)
- Vivekanandan S, Andrew CE:** Cross-reaction of human chorionic gonadotrophin in Immulite 2000 luteinizing hormone assay, 318 (SR)
- Vranken G.** *see* Bossuyt X
- Walker IAL, Nelson-Piercy C, Williamson C:** Role of bile acid measurement in pregnancy, 105 (RA)
- Walker M.** *see* Emberson JR
- Walker PL.** *see* Ismail AAA
- Walker V, Mills GA:** Solid-phase extraction in clinical biochemistry, 464 (RA)
- Wallace AM.** *see* Hogg JE
- Ward A.** *see* Patel D
- Watson ID.** *see* Thomas SHL; van Heyningen C
- Wheeler MJ.** *see* le Roux CW
- Whincup PH.** *see* Emberson JR
- White GH.** *see* Peake MJ
- Widdop B:** Analysis of carbon monoxide, 378 (RA)
- Wild G.** *see* Patel D
- Wiles D.** *see* Baxter GJ
- Williams AJ, Norris L, Coakley JC:** Artefactual reduction in plasma total carbon dioxide concentration in children, 62 (SR)
- Williams K.** *see* Spencer K
- Williamson C.** *see* Walker IAL
- Willis R.** *see* Payn MM
- Wood P.** *see* Armston A
- Worwood M:** Serum transferrin receptor assays and their application, 221 (RA)
- Wright J.** *see* Arasaradnam MP
- Yamada S.** *see* Masuda M
- Yamada Y.** *see* Miida T
- Yasuda S.** *see* Itoh S
- Yoon YM.** *see* Hong SH
- Yusa Y.** *see* Masuda M

## Subject index to Volume 39, 2002

(C) = Comment: (PV) = Personal View: (RA) = Review Article: (ER) = Evidence-based Review:  
(OA) = Original Article: (SR) = Short Report: (CR) = Case Report: (L) = Letter.

### Abbot IMx insulin assay

Rapid measurement of insulin using the Abbot IMx: application to the management of insulinoma, 513 (SR)

### Adrenal hyperplasia, congenital

Application of polymerase chain reaction with oligoligation assay to determine genotype in individuals presenting with congenital adrenal hyperplasia, 293 (OA)

### Adrenal insufficiency

Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?, 148 (SR)

### Ageing

Effect of ageing on plasma lipoprotein(a) levels, 237 (OA)

### Albumin measurement

Sample matrix is critical in the evaluation of a dry-slide bromocresol green method for human albumin, 311 (SR)

### Alcohol abuse

Survival after very high blood alcohol concentrations, 416 (L)

Survival after very high blood alcohol concentrations, author's reply, 416 (L)

### Analytical quality specifications

Combination of analytical quality specifications based on biological within- and between-subject variation, 543 (PV)

### Anaphylaxis

Anaphylactic reaction to intravenous sinistrin (Inutest), 76 (CR)

### Angina

Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome, 392 (OA)

### Anti-ovalbumin IgA

Immune complex transfer enzyme immunoassay for anti-ovalbumin IgA in serum, 482 (OA)

### Antiretroviral therapy, highly active

Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy, 409 (CR)

### Apolipoprotein A-I

Apolipoprotein A-I concentration in tears in diabetic retinopathy, 56 (OA)

### Arterial blood gas analysis

Arterial blood gas analysis: selecting the clinically appropriate option for calculating base excess, 614 (CR)

### Ascorbic acid stability

Stability of ascorbic acid in serum and plasma prior to analysis, 518 (SR)

### Asp70His

Naturally occurring mutation, Asp70His, in human butyrylcholinesterase, 154 (SR)

### AVL Omni 9 blood glucose analyser

Point-of-care testing of blood glucose in the neonatal unit using the AVL Omni 9 analyser, 509 (OA)

### b-thalassaemia heterozygote

Molecular analysis of a Thai b-thalassaemia heterozygote with normal haemoglobin A<sub>2</sub> level: implication for population screening, 44 (OA)

### Base excess extracellular fluid

Arterial blood gas analysis: selecting the clinically appropriate option for calculating base excess, 617 (CR)

### Bayer Rapidlab 860 blood glucose analyser

Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit, 502 (OA)

### Bile acid measurement

Role of bile acid measurement in pregnancy, 105 (RA)

### Blood glucose analysis

Continuous glucose monitoring and haemoglobin A<sub>1c</sub>, 516 (SR)

Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit, 502 (OA)

Point-of-care testing of blood glucose in the neonatal unit using the AVL Omni 9 analyser, 509 (OA)

### Blood pressure regulation

Assay of catechol-O-methyltransferase activity in human erythrocytes using norepinephrine as a natural substrate, 589 (OA)

**Blood specimen contamination**

Effects of contamination of blood specimens with liquid potassium-EDTA anticoagulant, 273 (OA)

**Book reviews**

Barth H, Butler GE, Hammond P: Hooper J, Sherwood R, Marshall W editors: *Biochemical Investigations in Laboratory Medicine*: 2001, 320

Bellio F, Mogensen CE, editors: *New Concepts in Diabetes and its Treatments*, 2000, 415

Brooks ZC: *Performance Driven Quality Control*, 2001, 414

Caughey, B, editor: *Advances in Protein Chemistry*, Vol 57: *Prion Proteins*: 2001, 163

Devlin TM, editor: *Textbook of Biochemistry with Clinical Correlations*, 5th Edn., 538

Fraser CG: *Biological Variation: from Principles to Practice*: 2001, 321

Freedman DB, Hooper J, Wood PJ, editors: *Challenges at the Clinical Interface: Case Histories for Clinical Biochemists*: 2001, 321

Lidsey JE: *The Bigger Bang*: 2002, 623

Liebler DC: *Introduction to Proteomics: Tools for the New Biology*, 538

Simopoulos AP, Visioli F, editors: *Mediterranean Diet Vol. 87*, 2000, 414

Thompson IM, Resnick MI, Klein EA, Totowa NJ, editors: *Prostate Cancer Screening*: 2001, 320

**Brain natriuretic peptide**

Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age, 151 (SR)

**Breast cancer**

Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry, 281 (OA)

**Breast-feeding**

Effect of breast-feeding on concentration of nitric oxide in breast milk, 68 (SR)

**Bromocresol green**

Sample matrix is critical in the evaluation of a dry-slide bromocresol green method for human albumin, 311 (SR)

**Butyrylcholinesterase**

Naturally occurring mutation, Asp70His, in human butyrylcholinesterase, 154 (SR)

**C-reactive protein**

Biochemical markers of neonatal sepsis: value of procalcitonin in the emergency setting, 130 (OA)

Limited clinical utility of high-sensitivity plasma C-reactive protein assays, 85 (C)

**Calcium measurement in urine**

Spot urine analysis: acidification does not increase calcium recovery, 64 (SR)

**Carbon monoxide exposure**

Analysis of carbon monoxide, 378 (RA)

**Carcinoid disease**

Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease, 577 (OA)

**Cardiac disease**

HDL-cholesterol and cardiac disease: which table to use?, 12 (RA)

**Cardiac troponin I**

Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome, 392 (OA)

Evaluation of Kryptor cardiac troponin I immunoassay, 145 (SR)

**Cardiovascular disease**

Cardiovascular disease and osteoporosis: is there a link between lipids and bone?, 203 (RA)

Limited clinical utility of high-sensitivity plasma C-reactive protein assays, 85 (C)

**Cholesterol**

Ethnic differences in total and HDL cholesterol concentrations: Caucasians compared with predominately Punjabi Sikh Indo-Asians, 609 (SR)

HDL-cholesterol and cardiac disease: which table to use?, 12 (RA)

LDL-cholesterol and HDL-cholesterol concentrations decrease during the day, 241 (OA)

**Chorionic gonadotrophin**

Cross-reaction of human chorionic gonadotrophin in Immulite 2000 luteinizing hormone assay, 318 (SR)

**Circadian rhythms**

Diurnal variation in lipoprotein lipase activity, 136 (OA)

LDL-cholesterol and HDL-cholesterol concentrations decrease during the day, 241 (OA)

**Clinical budgeting**

Quarts out of pint pots - expanding the pint. Clinical budgeting in practice, 340 (PV)

**Clinical governance**

Clinical governance: implications for point-of-care testing, 421 (C)

**Colorectal cancer**

Screening for colorectal cancer, 351 (PV)

**Complement 3d**

Novel nephelometric assay for measurement of complement 3d, 34 (OA)

**Computer simulation programmes**

Application of computer simulation analysis to assess the effects of relocating a hospital phlebectomy department, 261 (OA)

**Coronary heart disease**

Ethnic differences in total and HDL cholesterol concentrations: Caucasians compared with predominately Punjabi Sikh Indo-Asians, 609 (SR)



**Coronary syndromes, acute**

- Troponin for acute coronary syndromes, 624 (L)
- Troponin for acute coronary syndromes: has NICE got it right?, 194 (PV)

**Cortisol, serum**

- Free cortisol index as a surrogate marker for serum free cortisol, 406 (SR)
- Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?, 148 (SR)

**Creatinine**

- Creatinine assays: time for action?, 599 (SR)
- Reporting of creatinine concentration, 162 (L)

**Creutzfeldt-Jakob disease**

- Biochemical investigations in patients with dementia, 211 (RA)

**Cyclosporin**

- Cyclosporin: revisions in monitoring guidelines and review of current analytical methods, 424 (PV)

**Cyclosporin A**

- Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients, 70 (SR)

**Cystatin C**

- Cystatin C, 89 (PV)
- Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders, 308 (SR)

**Cystic fibrosis**

- Biological variation in sweat sodium chloride conductivity, 39 (OA)

**D-amino acid oxidase activity**

- Determination of D-amino acid oxidase activity in tumour cells, 595 (OA)

**Daidzein**

- Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry, 281 (OA)

**Dementia**

- Biochemical investigations in patients with dementia, 211 (RA)

**Diabetic retinopathy**

- Apolipoprotein A-I concentration in tears in diabetic retinopathy, 56 (OA)

**Down's syndrome**

- Current state of screening for Down's syndrome, 1 (RA)
- Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy, 567 (OA)
- Triploid pregnancy detected incidentally by Down's syndrome screening, 157 (CR)

**Enzyme-linked immunosorbent assays (ELISAs)**

- Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay

is potentially less specific than by immunofluorescence, 304 (OA)

Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein, 404 (SR)

Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay, 398 (OA)

**Erythrocyte catechol-O-methyltransferase**

Assay of catechol-O-methyltransferase activity in human erythrocytes using norepinephrine as a natural substrate, 589 (OA)

**(EZ)-cyclobilirubin**

Influence of glucuronosyl bilirubin and (EZ)-cyclobilirubin on determination of serum unbound bilirubin by UB-analyser, 583 (OA)

**Faecal fat**

Faecal fat: time to give it up, 77 (L)

**Fasting and metabolic variables**

Biochemical measures in a population-based study: effect of fasting duration and time of day, 493 (OA)

**Fibrinogen**

Biochemical markers of neonatal sepsis: value of procalcitonin in the emergency setting, 130 (OA)

**Fijian type 2 diabetes mellitus**

Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose, 606 (SR)

 **$\gamma$ -Glutamyltransferase**

$\gamma$ -Glutamyltransferase: value of its measurement in paediatrics, 22 (RA)

$\gamma$ -Glutamyltransferase: value of its measurement in paediatrics: errata, 323

 **$\gamma$  Heavy chain disease**

$\gamma$  Heavy chain disease screening showing a discrepancy between electrophoretic and nephelometric determinations of serum  $\gamma$  globulin concentration, 531 (CR)

**Gammaglobulin subclasses.** *see* IgG subclasses

**Gas chromatography-mass spectrometry**

Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry, 281 (OA)

**Genetic mutations and butyrylcholinesterase**

Naturally occurring mutation, Asp70His, in human butyrylcholinesterase, 154 (SR)

**Genetic polymorphism**

Analysis of serum angiotensin-converting enzyme, 436 (PV)

**Genistein**

Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry, 281 (OA)

**Glucuronosyl bilirubin**

Influence of glucuronosyl bilirubin and (EZ)-cyclo-bilirubin on determination of serum unbound bilirubin by UB-analyser, 583 (OA)

**Glycated haemoglobin**

Standardization of glycated haemoglobin, 78 (L), 534 (L)

Standardization of glycated haemoglobin - authors' reply, 534 (L)

**Glycogen in erythrocytes**

An improved quantitative assay of glycogen in erythrocytes, 612 (SR)

**Glycoprotein IIb/IIIa inhibitors**

Troponin for acute coronary syndromes, 624 (L)

Troponin for acute coronary syndromes: has NICE got it right?, 194 (PV)

**HaeIII polymorphism**

Association between *HaeIII* polymorphism of scavenger receptor class B type I gene and plasma HDL-cholesterol concentration, 478 (OA)

**Haemoglobin A<sub>1c</sub>**

Continuous glucose monitoring and haemoglobin A<sub>1c</sub>, 516 (SR)

Standardization of glycated haemoglobin, 534 (L)

Standardization of glycated haemoglobin - authors' reply, 534 (L)

**Haemolysis assessment**

Discrepancy between visual and spectrophotometric assessment of sample haemolysis, 521 (SR)

**High-density lipoprotein-cholesterol**

Association between *HaeIII* polymorphism of scavenger receptor class B type I gene and plasma HDL-cholesterol concentration, 478 (OA)

Ethnic differences in total and HDL cholesterol concentrations: Caucasians compared with predominately Punjabi Sikh Indo-Asians, 609 (SR)

HDL-cholesterol and cardiac disease: which table to use?, 12 (RA)

LDL-cholesterol and HDL-cholesterol concentrations decrease during the day, 241 (OA)

**Heterophilic antibodies**

Falsely increased prostate-specific antigen concentration attributed to heterophilic antibodies, 160 (CR)

**Hormone replacement therapy**

Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a

concentration of plasma oestradiol to protect against osteoporosis?, 184 (PV)

**Hospital reorganisation monitoring**

Application of computer simulation analysis to assess the effects of relocating a hospital phlebectomy department, 261 (OA)

**HTLV-1-associated myelopathy/tropical spastic paraparesis**

Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, 603 (SR)

**Human immunodeficiency virus**

Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy, 409 (CR)

**5-hydroxyindole acetic acid**

Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease, 577 (OA)

**Hyperamylasaemia**

Hyperamylasaemia and multiple myeloma, 616 (CR)

**Hypercholesterolaemia**

Japanese familial hypercholesterolaemia with a 327insC mutation in the LDL receptor gene, 526 (CR)

**Hypertriglyceridaemia**

Severe hypertriglyceridaemia associated with human immunodeficiency virus and highly active antiretroviral therapy, 409 (CR)

**Hypothyroidism, subclinical**

Audit of investigation of subclinical hypothyroidism in Scottish laboratories, 26 (OA), 535 (L)

Audit of investigation of subclinical hypothyroidism in Scottish laboratories - author's reply, 536 (L)

**Immulite 2000 luteinizing hormone assay**

Cross-reaction of human chorionic gonadotrophin in Immulite 2000 luteinizing hormone assay, 318 (SR)

Immulite 2000 LH assay: manufacturer's reply, 417 (L)

**Immune complex transfer enzyme immunoassay**

Immune complex transfer enzyme immunoassay for anti-ovalbumin IgA in serum, 482 (OA)

**Immunoassays and antibody interference**

Interference in immunoassay is an underestimated problem, 366 (PV)

**Immunofluorescence assays**

Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay is potentially less specific than by immunofluorescence, 304 (OA)

**Immunoglobulin G  $\kappa$** 

Macro-alkaline phosphatase due to IgG  $\kappa$  complex: demonstration with polyethylene glycol precipitation and immunofixation, 523 (CR)

**Immunoglobulin G subclasses**

Are there any clinical indications for measuring IgG subclasses?, 374 (RA)

**Impaired fasting glucose**

Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose, 606 (SR)

**Impaired glucose tolerance**

Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose, 606 (SR)

**Indo-Asians and coronary heart disease**

Ethnic differences in total and HDL cholesterol concentrations: Caucasians compared with predominately Punjabi Sikh Indo-Asians, 609 (SR)

**Insulin assay**

Rapid measurement of insulin using the Abbot IMx: application to the management of insulinoma, 513 (SR)

**Insulinoma**

Rapid measurement of insulin using the Abbot IMx: application to the management of insulinoma, 513 (SR)

**Intravenous sinistrin and anaphylaxis**

Anaphylactic reaction to intravenous sinistrin (Inutest), 76 (CR)

**Japanese familial hypercholesterolaemia**

Japanese familial hypercholesterolaemia with a 327insC mutation in the LDL receptor gene, 526 (CR)

**Journal Watch, 82, 164, 324, 418, 540, 624****Kryptor cardiac troponin I immunoassay**

Evaluation of Kryptor cardiac troponin I immunoassay, 145 (SR)

**Labels**

Stains, labels and detection strategies for nucleic acids assays, 114 (RA)

**Low-density lipoprotein-cholesterol**

LDL-cholesterol and HDL-cholesterol concentrations decrease during the day, 241 (OA)

**Low-density lipoprotein receptor gene mutation**

Japanese familial hypercholesterolaemia with a 327insC mutation in the LDL receptor gene, 526 (CR)

**Lipoprotein lipase activity**

Diurnal variation in lipoprotein lipase activity, 136 (OA)

**Lipoprotein(a)**

Effect of ageing on plasma lipoprotein(a) levels, 237 (OA)

**Lipoproteins**

LDL-cholesterol and HDL-cholesterol concentrations decrease during the day, 241 (OA)

**Literature searches**

Using Medline to achieve an evidence-based approach to diagnostic clinical biochemistry, 345 (PV)

**M2 anti-mitochondrial antibodies**

Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay is potentially less specific than by immunofluorescence, 304 (OA)

**Macro-alkaline phosphatase**

Macro-alkaline phosphatase due to IgG  $\phi$  complex: demonstration with polyethylene glycol precipitation and immunofixation, 523 (CR)

**Medline**

Using Medline to achieve an evidence-based approach to diagnostic clinical biochemistry, 345 (PV)

**Metabolic disorders, inherited**

Pregnancy and inherited metabolic disorders: maternal and fetal complications, 444 (RA)

**Mitochondrial dysfunction**

Mitochondrial dysfunction and the role of the non-specialist laboratory, 456 (RA)

**Mycophenolic acid**

Monitoring mycophenolic acid, 173 (PV)

**Myelin basic protein detection**

Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, 603 (SR)

**Myeloma, multiple, and hyperamylasaemia**

Hyperamylasaemia and multiple myeloma, 619 (CR)

**Myocardial injury after surgery**

Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome, 392 (OA)

**Neonatal blood glucose analysis**

Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit, 502 (OA)

Point-of-care testing of blood glucose in the neonatal unit using the AVL Omni 9 analyser, 509 (OA)

#### Neonatal sepsis

Biochemical markers of neonatal sepsis: value of procalcitonin in the emergency setting, 130 (OA)

#### Nephelometric assay

Novel nephelometric assay for measurement of complement 3d, 34 (OA)

#### NICE

Troponin for acute coronary syndromes: has NICE got it right?, 194 (PV)

#### Nitric oxide in breast milk

Effect of breast-feeding on concentration of nitric oxide in breast milk, 68 (SR)

#### Nucleic acids assays

Stains, labels and detection strategies for nucleic acids assays, 114 (RA)

#### Obstetric cholestasis

Role of bile acid measurement in pregnancy, 105 (RA)

#### Oestradiol

Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis?, 184 (PV)

#### Oligoligation chain reaction

Application of polymerase chain reaction with oligoligation assay to determine genotype in individuals presenting with congenital adrenal hyperplasia, 293 (OA)

#### Osteoclast formation

Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses, and potential therapeutic agents and biochemical markers, 551 (RA)

#### Osteodystrophy

Comparison of intact and 'whole molecule' parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy, 314 (SR)

#### Osteoporosis

Cardiovascular disease and osteoporosis: is there a link between lipids and bone?, 203 (RA)

Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis?, 184 (PV)

#### Osteoprotegerin

Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses, and poten-

tial therapeutic agents and biochemical markers, 551 (RA)

#### Paediatric plasma total carbon dioxide

Artefactual reduction in plasma total carbon dioxide concentration in children, 62 (SR)

#### Paediatrics

g-Glutamyltransferase: value of its measurement in paediatrics, 22 (RA)

#### Parathyroid hormone

Parathyroid hormone: what are we measuring and does it matter?, 169 (C)

#### Parathyroid hormone assays

Comparison of intact and 'whole molecule' parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy, 314 (SR)

#### Patient views

Review of a pilot quality-assessment program for interpretative comments, 250 (OA)

#### Phaeochromocytoma

Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines, 557 (OA)

#### Phlebotomy

Application of computer simulation analysis to assess the effects of relocating a hospital phlebotomy department, 261 (OA)

#### Plasma C-reactive protein assays, high-sensitivity

Limited clinical utility of high-sensitivity plasma C-reactive protein assays, 536 (L)

#### Plasma phenylalanine

Quantitative determination of plasma phenylalanine and tyrosine by electrospray ionization tandem mass spectrometry, 73 (SR)

#### Plasma total carbon dioxide

Artefactual reduction in plasma total carbon dioxide concentration in children, 62 (SR)

#### Plasma tyrosine

Quantitative determination of plasma phenylalanine and tyrosine by electrospray ionization tandem mass spectrometry, 73 (SR)

#### Pneumovax

Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay, 398 (OA)

#### Point-of-care testing

Clinical governance: implications for point-of-care testing, 421 (C)

Near-patient testing of blood glucose using the Bayer Rapidlab 860 analyser in a regional neonatal unit, 502 (OA)

Point-of-care testing of blood glucose in the neonatal unit using the AVL Omni 9 analyser, 509 (OA)



**Poisoned patients**

- Laboratory analyses for poisoned patients, 327 (C)
- Laboratory analyses for poisoned patients: joint position paper, 328 (G)

**Polymerase chain reaction**

- Application of polymerase chain reaction with oligoligation assay to determine genotype in individuals presenting with congenital adrenal hyperplasia, 293 (OA)

**Potassium-EDTA**

- Effects of contamination of blood specimens with liquid potassium-EDTA anticoagulant, 273 (OA)

**Pregnancy and inherited metabolic disorders**

- Pregnancy and inherited metabolic disorders: maternal and fetal complications, 444 (RA)

**Procalcitonin**

- Biochemical markers of neonatal sepsis: value of procalcitonin in the emergency setting, 130 (OA)

**Proliferative haematological disorders**

- Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders, 308 (SR)

**Prostate cancer**

- Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry, 281 (OA)

**Prostate-specific antigen concentration**

- Falsely increased prostate-specific antigen concentration attributed to heterophilic antibodies, 160 (CR)

**Pseudohypernatraemia**

- Effect of low protein concentration on serum sodium measurement: pseudohypernatraemia and pseudonormonatreaemia!, 66 (SR)

**Pseudonormonatreaemia**

- Effect of low protein concentration on serum sodium measurement: pseudohypernatraemia and pseudonormonatreaemia!, 66 (SR)

**Quality monitoring**

- Combination of analytical quality specifications based on biological within- and between-subject variation, 543 (PV)
- Review of a pilot quality-assessment program for interpretative comments, 250 (OA)

**Receptor activator for nuclear factor kappaB ligand**

- Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses, and potential therapeutic agents and biochemical markers, 551 (RA)

**Roche 917 clinical chemistry analyser**

- Discrepancy between visual and spectrophotometric assessment of sample haemolysis, 521 (SR)

**Salicylic acid in urine**

- Identification and determination of salicylic acid and salicyluric acid in urine of people not taking salicylate drugs, 50 (OA)

**Salicyluric acid in urine**

- Identification and determination of salicylic acid and salicyluric acid in urine of people not taking salicylate drugs, 50 (OA)

**Scavenger receptor class B type I gene**

- Association between *HaeIII* polymorphism of scavenger receptor class B type I gene and plasma HDL-cholesterol concentration, 478 (OA)

**Serotonin, whole blood**

- Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease, 577 (OA)

**Serotype-specific antibody measurement**

- Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay, 398 (OA)

**Serum angiotensin-converting enzyme**

- Analysis of serum angiotensin-converting enzyme, 436 (PV)

**Serum globulin  $\gamma$  concentration**

- $\gamma$  Heavy chain disease screening showing a discrepancy between electrophoretic and nephelometric determinations of serum  $\gamma$  globulin concentration, 531 (CR)

**Serum magnesium**

- Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients, 70 (SR)

**Serum sodium measurement**

- Effect of low protein concentration on serum sodium measurement: pseudohypernatraemia and pseudonormonatreaemia!, 66 (SR)

**Serum unbound bilirubin analysis**

- Influence of glucuronosyl bilirubin and (EZ)-cyclo-bilirubin on determination of serum unbound bilirubin by UB-analyser, 583 (OA)

**Shewhart 'c' control charts**

- Optimizing the availability of 'stat' laboratory tests using Shewhart 'c' control charts, 140 (OA)

**Sialic acid**

- Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose, 606 (SR)



**Solid-phase extraction**

Solid-phase extraction in clinical biochemistry, 464 (RA)

**Spot urine analysis**

Spot urine analysis: acidification does not increase calcium recovery, 64 (SR)

**Stains**

Stains, labels and detection strategies for nucleic acids assays, 114 (RA)

**'Stat' laboratory tests**

Optimizing the availability of 'stat' laboratory tests using Shewhart 'c' control charts, 140 (OA)

**Statins**

Cardiovascular disease and osteoporosis: is there a link between lipids and bone?, 203 (RA)

**Sweat conductivity**

Biological variation in sweat sodium chloride conductivity, 39 (OA)

**Synacthen tests**

Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?, 148 (SR)

**Tacrolimus**

Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry, 487 (OA)

**Tandem mass spectrometry assay**

Quantitative determination of plasma phenylalanine and tyrosine by electrospray ionization tandem mass spectrometry, 73 (SR)

**Thyroglobulin**

Can we measure serum thyroglobulin?, 196 (PV)

**Thyroid cancer**

Can we measure serum thyroglobulin?, 196 (PV)

**Transferrin**

Serum transferrin receptor assays and their application, 221 (RA)

**Triploid pregnancy detection**

Triploid pregnancy detected incidentally by Down's syndrome screening, 157 (CR)

**Trisomy 21**

Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy, 567 (OA)

**Troponin**

Troponin for acute coronary syndromes, 621 (L)

Troponin for acute coronary syndromes: has NICE got it right?, 194 (PV)

**Troponin I**

Decision limit for troponin I and assay performance, 231 (OA)

**Urinary free metadrenalines**

Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines, 557 (OA)

**Ventricular function, left**

Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age, 151 (SR)

